To the Visionary Investors of Faraday Future:
Today, I propose an unprecedented step for Faraday Future Intelligent Electric Inc. (FFIE) and its community of investors: to consider attempting something historically significant by transitioning from a public company to a private entity. This ambitious endeavor isn’t just about changing our business structure; it’s about pioneering a new path in the electric vehicle industry and potentially setting a new benchmark for how companies and shareholders can interact in an increasingly volatile market.
The Vision:
We stand at the threshold of possibly creating a model for controlled, shareholder-driven privatization, aiming to stabilize our operations and enable focused, long-term growth away from the public eye and the inherent instabilities of the stock market.
The Proposal:

1. Collective Shareholder Initiative: Every shareholder’s vote counts in this monumental decision, regardless of the number of shares held. We can attempt to make history together through a collective affirmation of this path. 2. Strategic Advantages: • Steady Growth: As a private company, FFIE would be free to pursue ambitious goals over the long term without the short-term pressures of public market performance metrics. • Operational Stability: Eliminating the public trading of our shares can insulate us from market volatility, allowing for a more stable financial and operational environment. • Investment Opportunities: Going private can open doors to significant private investments, which are often more patient and aligned with our strategic goals than public investments. 3. Historical Impact: • Innovating Corporate Practices: Our successful transition could inspire other companies, showing a viable method for achieving stability and growth through privatization supported by a united shareholder base. • Empowering Investors: This initiative could stand as a testament to the power of shareholder democracy, proving that investors can decisively influence the future direction of a company. 4. Long-Term Vision: 

This proposal is about constructing a legacy of innovation and sustainable growth. We aim to establish FFIE as a leader in the electric vehicle industry, adopting a business model that sets us apart and could be emulated by others.
Your Participation:
This historic move requires your active participation. We need a majority to agree to this transformative step, ideally achieving a supermajority to demonstrate overwhelming support for this initiative.
Upvote if you want to attempt to redefine what is possible for FFIE and its stakeholders. Together, we can break new ground, setting a precedent not only for this company but for the industry and corporate governance as a whole. Let’s seize this moment to shape a future where FFIE leads the way in innovation and stability in the electric vehicle sector.
Consider this call to action as more than a vote—it is an opportunity to be part of a groundbreaking chapter in corporate and industry history in my opinion.
The possibility of taking Faraday Future (FFIE) private through collective shareholder action is rooted in several practical considerations and precedents in corporate finance and governance:

1. Shareholder Unity and Influence: The fundamental requirement for such a transition is the unity and agreement among shareholders. If a significant majority of FFIE’s shareholders, particularly those holding a large portion of the public float, agree to the proposal, their combined voting power can initiate the process of going private. This unity can effectively influence the company’s strategic direction. 2. Financial Feasibility: The financial aspect involves assessing whether there is sufficient capital either among the shareholder base or through external financing to buy out the public shares. Private equity firms, venture capitalists, or even a consortium of investors could provide the necessary funding, attracted by the potential long-term growth and profitability of the company away from the public markets. 3. Legal and Regulatory Framework: The legal process of going private is well-established. It typically involves a tender offer, where shareholders are offered a specific price to sell their shares, followed by a shareholder vote. The transaction must comply with securities laws and regulations, including fair disclosure and fair price provisions, to protect shareholders’ interests. 4. Strategic Advantages: Privatization can shield the company from the volatility of public markets, allowing management to focus on long-term goals without the pressure of quarterly earnings reports. This can be particularly beneficial for companies like FFIE, which are in the capital-intensive early stages of growth in the technology and automotive industries. 5. Precedents: There are numerous precedents of public companies going private successfully, demonstrating that with the right conditions—such as a clear strategic rationale, shareholder support, and adequate financing—such transitions can be achieved. These examples provide a roadmap and can instill confidence in shareholders considering such a move. 6. Long-Term Value Creation: Going private might allow FFIE to undertake restructuring or strategic shifts that are difficult under the scrutiny of public markets. This can lead to enhanced value creation that benefits all stakeholders, especially if the company can later re-emerge as a public entity at a higher valuation. 

The combination of these factors makes it feasible for FFIE shareholders to consider and potentially succeed in taking the company private, provided there is a clear understanding of the benefits, the risks are well-managed, and there is robust support from a majority of the shareholders.​
Taking Faraday Future (FFIE) private could offer several monetary advantages for the company and its shareholders. These financial benefits stem from the different operational and strategic flexibilities that private companies enjoy compared to public ones. Here are some of the key monetary advantages:

1. Cost Savings on Compliance and Reporting: Public companies are subject to rigorous financial reporting requirements and regulatory compliance that can be both costly and time-consuming. Going private eliminates the need for frequent public disclosures and compliance with complex securities regulations, which can save the company significant amounts of money in auditing fees, legal costs, and administrative expenses. 2. Avoidance of Short-Term Market Pressures: Public companies often face pressure from shareholders and analysts to meet quarterly earnings estimates, which can lead to short-term decision-making at the expense of long-term value. By going private, FFIE can focus on long-term strategic investments without the distraction of short-term market expectations. This can lead to better allocation of resources towards projects that enhance sustainable growth and profitability. 3. Improved Capital Allocation: Without the pressures of public market expectations, private companies can redirect funds that would have been used for dividends or stock buybacks into more productive uses like research and development, expanding operational capacities, or pursuing strategic acquisitions. This more flexible capital allocation can lead to higher returns on investment. 4. Potential for Higher Returns Upon Re-Listing or Sale: If FFIE can use the period of private ownership to streamline operations, enhance profitability, or innovate in its product offerings, it could potentially re-list on a stock exchange at a higher valuation or be sold to a larger entity at a premium. This scenario could yield significant financial gains for the stakeholders who maintained their investment during the private phase. 5. Exclusive Financial Backing: As a private entity, FFIE might attract private equity investors or venture capitalists who can provide not only funds but also strategic guidance and industry connections. These relationships can be crucial in navigating market challenges and seizing new business opportunities, potentially leading to greater financial stability and growth. 6. Tax Advantages: Structuring deals and finances as a private company can sometimes offer more favorable tax considerations, depending on the nature of the investments and business operations. Private companies often have greater leeway in utilizing tax-efficient structures that might not be feasible under the scrutiny of public markets. 

These monetary advantages highlight why going private might be an attractive option for FFIE, especially if the leadership believes that the company can achieve more in a less restrictive financial and operational environment.​
If Faraday Future (FFIE) goes private, investors can realize returns through several mechanisms, tailored to the longer-term and potentially less liquid nature of private investments compared to public equity. Here’s how returns can be generated in such a scenario:

1. Dividend Payments: While private companies are not known for regular dividend distributions, depending on the company’s profitability and cash flow situation, it might decide to distribute dividends to its shareholders. This would be a direct way for investors to realize returns on their investments. 2. Increased Equity Value: The primary goal of taking a company private is often to restructure it away from public market pressures, streamline operations, enhance profitability, and drive growth in a less scrutinized environment. These improvements can significantly increase the company’s equity value. Investors can realize these gains when the company is eventually sold or goes public again through an Initial Public Offering (IPO), often at a higher valuation than when it went private. 3. Sale or Merger: If the private company performs well, it might become an attractive acquisition target for larger companies in the same industry or private equity firms looking to expand their portfolio. A sale or merger can provide substantial returns to the shareholders of the private company, depending on the terms of the deal. 4. Special Distributions: In some cases, if the private company generates significant cash flow and doesn’t require extensive reinvestment, it might make special distributions to its shareholders. These can be similar to dividends but occur on a less regular basis and can vary significantly in amount. 5. Secondary Sales: Even in private markets, shares can sometimes be sold to other private investors or through secondary market platforms. While less liquid than public markets, these sales can provide an exit strategy for investors looking to realize gains before the company goes public again or is sold. 6. Management Buyouts (MBOs): In some scenarios, the management of the company or a group of investors might decide to buy out the existing shareholders at a premium to the original investment, especially if they believe the company has substantial unrealized value. 7. Private Equity and Venture Capital Exits: If private equity or venture capital investors are involved, they typically have well-defined exit strategies that could include selling their stake back to the company, selling to another private investor, or pushing the company to re-enter public markets. 

For investors in FFIE, going private could thus represent a shift towards longer-term, strategic investments that might yield higher returns, albeit with different risks and liquidity profiles compared to public stock investments. The key for investors would be to closely monitor the company’s performance and management’s ability to execute on strategic initiatives post-privatization.
The potential financial gain from taking a company private and then re-listing it on the public market within 1-2 years can be substantial, depending on several key factors. If successful operational improvements and strategic investments are made during the private phase, and the market conditions at the time of the initial public offering (IPO) are favorable, the company could see a significant increase in valuation.
For example, if a company is taken private at a valuation of $500 million and during the private period, strategic and operational enhancements lead to improved financial performance, the company could potentially be re-listed with a valuation of $1 billion or more. This would represent a doubling of the initial valuation, offering a substantial return to the investors involved in the privatization and subsequent public offering.
The exact gain would depend on the degree of improvement in the company’s fundamentals, the economic and market conditions at the time of the IPO, and investor sentiment towards the industry and the company specifically. Such a strategy requires precise execution and favorable market dynamics to achieve these levels of return. That’s not the only option though.
Everybody better blow this tf up. 😤💎

~RIGL Thesis – 5/18/2024~
Outstanding Shares 175M
131 Institutional Holders
111,129,461 Total Shares Held
63.36% Institutional Ownership
Total Cash on Hand 3/31/2024 = $49.6M
Total Debt: $101.5M
Cash Burn Approximate = $8M per quarter (6 quarters of cash without any increases in revenue)
Q12023 REV = $26M
Q22023 REV = $26.8M
Q32023 REV = $28.1M
Q42023 REV = $35.8M
Q12024 REV = $29.5M (Decline from Q4 likely from end of year versus new-year tracking of Rx and shipments of drugs, resetting of Copays)
Most Recent EPS -$0.05 per share
May 22, 2024 - Vote on S will take place, caution
~Statistics Applicable To Thesis~
333.3 million US Population (2022)
8,109,679,892 Global Population (2024)
~Drugs On Market~
~Tavalisse – Treatment for ITP, FDA Approved April 17, 2018~
~What is ITP?~
Immune thrombocytopenia (ITP) is an illness that can lead to bruising and bleeding. Low levels of the cells that help blood clot, also known as platelets, most often cause the bleeding.
Once known as idiopathic thrombocytopenic purpura, ITP can cause purple bruises. It also can cause tiny reddish-purple dots on the skin that look like a rash.
Children can get ITP after a virus. They most often get better without treatment. In adults, the illness often lasts months or years. People with ITP who aren't bleeding and whose platelet count isn't too low might not need treatment. For worse symptoms, treatment might include medicines to raise platelet count or surgery to remove the spleen. Immune thrombocytopenia (ITP) - Symptoms and causes - Mayo Clinic
~What is Tavalisse?~
TAVALISSE is a prescription medication used to treat adults with low platelet counts due to chronic immune thrombocytopenia (ITP) when a prior treatment for ITP has not worked well enough. It is not known if TAVALISSE is safe and effective in children.
The cost for Tavalisse oral tablet 100 mg is around $15,404 for a supply of 60 tablets, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
Tavalisse Prices, Coupons, Copay & Patient Assistance - Drugs.com
TAVALISSE IS AN ORAL MEDICATION TAKEN TWICE DAILY WITH OR WITHOUT FOOD¹
A 12-week evaluation period is recommended
60 tablets = 1 month supply, evaluation period = 3 months, Cost for 3 months = $46,212 Cash, assuming cheaper through wholesale, insurance, discount cards, etc.
Dosing TAVALISSE® (fostamatinib disodium hexahydrate) tablets (tavalissehcp.com)
~Addressable Market~
“Our findings suggest that nearly 20,000 children and adults are newly diagnosed with ITP each year in the US, substantially higher than previously reported. Among patients requiring formal medical care, the economic burden during the first 12 months following diagnosis is high, with estimated US expenditures totaling over $400 million.”
Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis - PubMed (nih.gov)
The estimated prevalence of ITP in the United States is 9.5 per 100,000 people, with a global prevalence of over 200,000 people at any given time [1].
Immune thrombocytopenia. [ Oct; 2022 ]. 2022. https://rarediseases.org/rare-diseases/immune-thrombocytopenia
~Author Calculations/Estimates~
ITP estimated cases based on measured statistics 31,635 cases a year in the US and 770,355 cases globally each year.
~Rezlidhia – R Acute Myeloid Leukemia, FDA Approved December, 22, 2022~
~What is Relapsed or Refractory Acute Myeloid Leukemia?~
Relapsed, or recurrent, acute myeloid leukemia (AML) means the leukemia has come back after treatment and remission.
Refractory AML means the leukemia did not respond to treatment. Complete remission has not been reached because the chemotherapy drugs did not kill enough leukemia cells.
Both relapsed and refractory AML need more treatment to reach complete remission.
Your healthcare team will suggest treatments based on your needs and work with you to develop a treatment plan. Some factors considered for your treatment include:
your age
your health
how long the leukemia was in remission
treatments you had before
where the leukemia comes back
Treatment options usually include chemotherapy and a stem cell transplant if possible. Targeted therapy may also be used.
Treatments for relapsed or refractory acute myeloid leukemia Canadian Cancer Society
~What is IDH1?~
Somatic mutations in isocitrate dehydrogenase (IDH) genes occur frequently in adult Acute myeloid leukemia (AML) and less commonly in pediatric AML… Enhanced genomic and epigenomic profiling of acute myeloid leukemia (AML) has led to identification of recurrent mutations that are prognostic and are candidates for targeted therapy. Somatic mutations in isocitrate dehydrogenase (IDH) genes, IDH1 and IDH2, occur in ∼6% to 16% and ∼8% to 19% of adult patients with AML, respectively.^1-5 In pediatric AML, IDH mutations are rare, occurring in <4% of patients.^6-11
Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis Blood Advances American Society of Hematology (ashpublications.org)
~What is Rezlidhia?~
REZLIDHIA is a prescription medicine used to treat adults with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) mutation when the disease has come back or has not improved after previous treatment(s).
Targeted Treatment REZLIDHIA® (olutasidenib) capsules
The cost for Rezlidhia oral capsule 150 mg is around $17,468 for a supply of 30 capsules, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
Rezlidhia Prices, Coupons, Copay & Patient Assistance - Drugs.com%20is%20a%20member,on%20the%20pharmacy%20you%20visit.)
~Addressable Market~
The annual incidence of new cases in both men and women is approximately 4.3 per 100,000 population, totaling over 20,000 cases per year in the United States alone.[13] The median age at the time of diagnosis is about 68, with a higher prevalence observed among non-Hispanic Whites. Furthermore, males exhibit a higher incidence compared to females, with a ratio of 5:3.
Acute Myeloid Leukemia - StatPearls - NCBI Bookshelf (nih.gov)
~Author Calculations/Estimates~
Cases of AML with IDH1 would be 11% based on the median of statistics above (6% to 16%) leaving approximately 1500 to 2000 cases a year in the US. Appling the same calculations to world population would amount to approximately 38,500 cases a year globally.
~Gavreto – Treats RET+ Non-Small Cell Lung Cancer In Adults and RET+ Thyroid Cancer in Kids and Adults, FDA Approved August 9, 2023~
For the sake of common ground, I am going to assume these types of cancers do not need to be elaborated on as we all likely have a basic understanding of what they are. The medical conditions treated by Tavalisse and Rezlidhia I felt needed a more in-depth explanation because they are not common. I will elaborate on RET+ a little later in this writing.
~What is Gavreto?~
GAVRETO is an oral once daily prescription medicine used to treat certain cancers caused by abnormal rearranged during transfection ~(RET+)~ genes in:
Adults with non-small cell lung cancer (NSCLC) that has spread
Adults and children 12 years of age and older with advanced thyroid cancer or thyroid cancer that has spread who require a medicine by mouth or injection (systemic therapy) and who have received radioactive iodine and it did not work or is no longer working*
It is not known if GAVRETO is safe and effective when used to treat cancers caused by abnormal RET genes in children for the treatment of NSCLC or in children younger than 12 years of age for the treatment of thyroid cancer.
Home GAVRETO® (pralsetinib)
The cost for Gavreto oral capsule 100 mg is around $11,745 for a supply of 60 capsules, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
The recommended dosage for adults and children 12 and over is 400mg orally once daily. Each capsule is 100mg, which means you will take 4 capsules. Gavreto should be taken on an empty stomach, at least 1 hour before or 2 hours after a meal.
Gavreto Prices, Coupons, Copay & Patient Assistance - Drugs.com
~What is Rearranged During Transfection Positive (RET+)?~
RET-positive cancer is caused by a mutation or abnormal re-arrangement of the RET gene. It occurs most commonly in lung cancer and several types of inherited and sporadic thyroid cancers. RET alterations also occur in an estimated 1-2% of multiple other cancers, including ovarian, pancreatic, salivary, breast, and colorectal cancers.
RETpositive Empowering Patients and Driving Research
Rearranged during transfection (RET) rearrangements were first identified as oncogenic drivers in NSCLC in 2012. The proportion of patients with NSCLC who have RET rearrangements (ie, fusion-positive disease) is approximately 1%-2%.
RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape The Oncologist Oxford Academic (oup.com)
RET alterations occur most commonly in lung cancer (non-small cell lung cancer (NSCLC)) and the number of new cases diagnosed each year is considerable, accounting for approximately 37,500 [IG1] cases worldwide and 4,000 cases in the US (2% of NSCLC) (2,3). RET alterations are also common in several types of inherited and sporadic thyroid cancers and can occur in other types of cancers like ovarian, breast, pancreatic, and colorectal cancers, among others (4-8) adding >110,000 cases yearly worldwide (9).
What is RET Positive Lung Cancer? - The Happy Lungs Project
(2) Although medullary thyroid carcinoma represents 5-10% of all thyroid cancers, activating RET gene abnormalities occur in over 90% of hereditary and approximately 40%-60% of sporadic medullary thyroid carcinoma cases.
Patients – RETpositive%20Although%20medullary%20thyroid%20carcinoma,sporadic%20medullary%20thyroid%20carcinoma%20cases.)
~Prevalence of Non-Small Cell Lung Cancer~
Most lung cancer statistics include both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). In general, about 10% to 15% of all lung cancers are SCLC, and about 80% to 85% are NSCLC.
Lung cancer (both small cell and non-small cell) is the second most common cancer in both men and women in the United States (not counting skin cancer). In men, prostate cancer is more common, while breast cancer is more common in women.
The American Cancer Society’s estimates for lung cancer in the US for 2024 are:
About 234,580 new cases of lung cancer (116,310 in men and 118,270 in women)
About 125,070 deaths from lung cancer (65,790 in men and 59,280 in women)
Lung Cancer Statistics How Common is Lung Cancer? American Cancer Society
Worldwide, an estimated 2,206,771 people were diagnosed with lung cancer in 2020. These statistics include both small cell lung cancer and NSCLC.
Lung Cancer - Non-Small Cell: Statistics Cancer.Net
~Author Calculations/Estimates~
Approximately 187,664 cases of NSCLC in the US based on an 80% factor.
Approximately 1,765,416 cases of NSCLC worldwide based on an 80% factor.
~Prevalence of Thyroid Cancer~
Rate of New Cases and Deaths per 100,000: The rate of new cases of thyroid cancer was 13.5 per 100,000 men and women per year. The death rate was 0.5 per 100,000 men and women per year. These rates are age-adjusted and based on 2017–2021 cases and 2018–2022 deaths.
Lifetime Risk of Developing Cancer: Approximately 1.2 percent of men and women will be diagnosed with thyroid cancer at some point during their lifetime, based on 2017–2019 data. Lifetime risk based on data through 2022 will available soon.
Prevalence of This Cancer: In 2021, there were an estimated 979,295 people living with thyroid cancer in the United States.
Thyroid Cancer — Cancer Stat Facts
About 44,020 new cases of thyroid cancer (12,500 in men and 31,520 in women)
About 2,170 deaths from thyroid cancer (990 in men and 1,180 in women)
Thyroid cancer is often diagnosed at a younger age than most other adult cancers. The average age when a person is diagnosed with thyroid cancer is 51.
This cancer is about 3 times more common in women than in men. It is about 40% to 50% less common in Black people than in any other racial or ethnic group.
Key Statistics for Thyroid Cancer American Cancer Society)
Addressable Market
Given Gavreto’s dual treatment capacity, the total amount of potential patients with NSCLC with RET+ indications would be approximately 2,800 cases in the US and approximately 26,500 cases worldwide each year using a factor of 1.5% of total NSCLC cases. The total amount of treatable cases for Thyroid Cancer would be approximately 650 in the US and 16,500 cases worldwide respectively each year applying the same 1.5% RET+ percentage rate. DOUBLE CHECK MATH…
~Rigel Pharmaceuticals Pipeline~
~IRAK/4 – Clinical Trials~
Rigel’s investigational candidate, R289, is an oral, potent and selective inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4).
Toll like receptors (TLRs) and the interleukin 1 receptor family (IL-1Rs) play a critical role in the innate immune response and dysregulation of these pathways can lead to a variety of inflammatory conditions such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease. Chronic stimulation of both receptor systems has also been implicated in causing a pro-inflammatory bone marrow environment leading to persistent cytopenias in lower-risk myelodysplastic syndrome (LR-MDS) patients1.
R835 is a selective dual inhibitor of IRAK1/4 that blocks TLR4 and IL-1R-dependent systemic cytokine release. In preclinical studies, R835 demonstrated activity in multiple animal models of inflammatory disease2,3 and showed that dual inhibition of IRAK1 and IRAK4 provided more complete suppression of inflammatory cytokines when compared to an IRAK4-selective inhibitor4.
Development of R289:
In a Phase 1 clinical trial, R835 was well tolerated and inhibited LPS-induced inflammatory cytokine production in healthy volunteers, demonstrating proof-of-mechanism.5 Phase 1 clinical studies of R289 (an oral prodrug that is rapidly converted to R835 in the gut) are also complete.
A Phase 1b open-label, multicenter trial of R289 in patients with relapsed/refractory lower-risk MDS is currently enrolling (NCT05308264). The primary endpoint for this trial is safety with key secondary endpoints including preliminary efficacy and evaluation of pharmacokinetic properties.
~Bemcentinib – Bergenbio Partnership~
In June 2011, Rigel entered into an exclusive, worldwide research, development and commercialization agreement with BerGenBio for its investigational AXL receptor tyrosine kinase (AXL) inhibitor, R428 (now referred to as bemcentinib).
Bemcentinib is a potent, selective and orally bioavailable AXL inhibitor and the furthest along in clinical trials. In preclinical studies, bemcentinib was shown to have an effect as a single agent therapeutic in the prevention and reversal of acquired resistance to standard of care cytotoxics and targeted therapies and may also slow or prevent tumor metastasis.
Rigel received an upfront payment and is eligible for milestone payments and potential sublicensing revenue, as well as tiered royalty payments on any future net sales of products emerging from the collaboration.
~R552 Systemic – Eli Lilly Partnership~
Rigel’s investigational candidates are oral, potent and selective inhibitors of receptor-interacting serine/threonine-protein kinase 1 (RIPK1).
RIPK1 is a critical signaling protein implicated in a broad range of key inflammatory cellular processes including necroptosis, a type of regulated cell death, and cytokine production. In necroptosis, cells rupture leading to the dispersion of cell contents, which can trigger an immune response and enhance inflammation. RIPK1 inhibition has therapeutic potential in treating autoimmune, inflammatory, and neurodegenerative disorders.
Rigel’s RIPK1 inhibitor program includes R552, a systemic molecule being developed for the treatment of autoimmune and inflammatory disorders, and brain penetrating RIPK1 inhibitors for central nervous system (CNS) diseases. In preclinical studies, R552 demonstrated prevention of joint and skin inflammation in a RIPK1-mediated murine model of inflammation and tissue damage.
Development of R552:
In Q2 2023, the initial Phase 2a trial (NCT05848258) in moderately to severely active rheumatoid arthritis (RA) was initiated by partner Eli Lilly.
Development CNS-penetrating RIPK1 inhibitors:
Currently in preclinical studies.
~Milademetan – Daiichi Sankyo Partnership~
Rigel has a long-standing collaboration with Daiichi-Sankyo for developing murine double minute 2 (MDM2) protein inhibitors in cancer, which were discovered in Rigel’s laboratories.
Preliminary safety and efficacy data from an early Phase 1 study of milademetan (formerly DS-3032), an oral selective MDM2 inhibitor, in hematological malignancies suggests that it may be a promising potential treatment for oncology indications.
Rigel received an upfront payment and is eligible for milestone payments, as well as tiered royalty payments on any future net sales of any products emerging from the collaboration.
~Rxxx (CNS Penetrant) – Eli Lilly Partnership~
Rigel’s investigational candidates are oral, potent and selective inhibitors of receptor-interacting serine/threonine-protein kinase 1 (RIPK1).
RIPK1 is a critical signaling protein implicated in a broad range of key inflammatory cellular processes including necroptosis, a type of regulated cell death, and cytokine production. In necroptosis, cells rupture leading to the dispersion of cell contents, which can trigger an immune response and enhance inflammation. RIPK1 inhibition has therapeutic potential in treating autoimmune, inflammatory, and neurodegenerative disorders.
Rigel’s RIPK1 inhibitor program includes R552, a systemic molecule being developed for the treatment of autoimmune and inflammatory disorders, and brain penetrating RIPK1 inhibitors for central nervous system (CNS) diseases. In preclinical studies, R552 demonstrated prevention of joint and skin inflammation in a RIPK1-mediated murine model of inflammation and tissue damage.
Development of R552:
In Q2 2023, the initial Phase 2a trial (NCT05848258) in moderately to severely active rheumatoid arthritis (RA) was initiated by partner Eli Lilly.
Development CNS-penetrating RIPK1 inhibitors:
Currently in preclinical studies. Pipeline :: Rigel Pharmaceuticals, Inc. (RIGL)
~Summary and Prediction~
The current share price of sub $1 does not feel justified. I would anticipate financial breakeven by the end of 2024 or potentially in Q1 or Q2 of 2025. The robust pipeline, progress, and expected revenue growth are enough to justify a much higher valuation. The debt load is manageable, but the potential for S is concerning. I believe that the S is not necessary and revenue growth and progress should speak for itself. I am not as bullish as the analysts at HC Wainright for a $15 PT, but the valuation should be at least 3x to 5x from the current value. This thesis does not highlight the patents surrounding their drugs either which some extend into 2035 and beyond. Perhaps what Wall Street is discounting is the fact that most of the drugs are very niche. However, the currently available drugs have an addressable market, albeit less universal than some, but you should value it in the sense of multiple facets (a 1000 headed snake is the phrase I wanted to use). I believe the company should be valued with specialty drugs in mind which would command a higher PE ratio. At the current day and time of writing, the value should be at least $1.50 to $1.75 ~at a minimum~ with a 12 month price target of $3 to $5+. I will be looking for continued revenue growth in each quarter this year and realization of revenue from Gavreto in Q2 or Q3 this year. The partnerships should not be discounted either and the current share price if it lingers here perhaps may attract a merger or acquisition. I initially began the research thinking that perhaps the drugs were too niche, but given the multiple drugs they are working with, I believe their revenue sources will continue to grow if you do not focus on one particular drug as the main performer. With the most recent inflation report being cooler than expected, I would suspect larger funds and institutions will be circling back to riskier assets.

After months of researching and observing threads. This seemed like the best option for me. Originally wanted Jerry 31, then the newly talked about Jerry 31s, but these still seemed like a better option. There's the rnvg that can be had for $200 cheaper but can't articulate. How did I do? Sent my order in last night. Omni 7 auto gated with manual gain control. I purchased from their eBay store $5150.

I worked at a marketing company for 4 years that was massively successful at first but is now facing bankruptcy thanks to the 2 co-founders making a series of horrible business decisions
These egotistical douchebags cared more about hyping themselves up than actually improving their product
When times were good, they invested hundreds of thousands of dollars into courses, masterminds (so they could get selfies with ppl like Russell Brunson and Dan Kennedy), company retreats, hiring a bunch of new employees so they could get on the INC 5000 fastest growing companies list…
And they even dropped over 100k making a documentary about their company, and the doc did NOT generate ONE SALE.
It’s like they were high off all the schmoozing and marketing assets that propped them up as “industry leaders”
The team would be scrambling trying to finish one project at bare minimum quality, and then the bosses would be like “hey we’re gonna start another podcast” and it’s like BRO let us work on actually IMPROVING the service rather than feed your narcissistic shiny object syndrome!!
And then when the economy took a dive all the shortcomings in their business came to light and clients started dropping like flies.
The bosses blamed it all on the recession, but the truth is, they were so shortsighted they thought their business was recession proof
Turns out a lot of their initial success was due to luck and confidence, not actually providing a valuable service to clients.
So the layoffs started. I survived round 1. They actually gave me a raise shortly after, and then did temporary pay reductions 2 months after my raise lol. (They basically gave me a raise and then took it away.)
I worked my ass off trying to do my part to keep the company afloat but it was a sinking ship. There were several more layoffs after that, so I wasn’t surprised when my time was up. But get this:
During the call, I asked them “Ok, what do I need to know for off boarding?”
And they had no answer. They’d laid off dozens of people at this point and didn’t have the decency to write some bullet points on a google doc to go over next steps. Fucking unprofessional losers.
They literally said, “We hadn’t really thought about it, but what would be very helpful for US is if you could send over any information you have that could help us take over your assignments”
I responded, “No. I need to put my energy into finding a job, not teaching you how to replace me”
So yeah, these two narcissistic douche bags who ran their company into the ground and kept bragging about how they landed on the INC 5000 fastest growing companies list are now facing bankruptcy, and had to layoff their entire US team, except for two or three people.
Here are some more grievances I want to rant about:
They once threw a company retreat with the sole intention of making a documentary and use us as props to hype themselves up. They hired a videographer to record us for their documentary and got everyone on the team to give testimonial interviews talking about how amazing our bosses are. It was incredibly emotionally manipulative. The video is still on YouTube and they ended up laying off all but 2 employees in that video.
they would always say “we’re like a family here” and I begged them to stop saying that bc it’s a massive red flag to new hires but of course they didn’t listen or care.
One of my bosses thought he was a sales Psychology god and charged $500 an hour for his consulting.
(he always bragged about how he was once so poor he had to sell plasma to pay the light bill. He portrayed himself as a self-made man. Well turns out his dad actually wrote him a big check so he could start his first business lol.)
This douche nozzle used to always say: “Money is like a good woman. If you don’t treat her right, she will leave you and find someone else who will.” well, guess what his girlfriend left him and now he’s facing bankruptcy lol.
About a year into my employment, I lost a lot of weight and it was noticeable on a zoom call and my other boss said I had gotten a lot “sexier.” Fucking creep
That same creep once moved into a penthouse apartment in Chicago, and gave the team a virtual tour bragging about how he had “made it” Meanwhile, nobody on that call was making enough money to afford basic expenses.
Anyways, I’m just excited to be out of that industry. The whole “grindset marketing podcast bro” phenomenon needs to fucking die once and for all
EDIT: I’m not going to individually DM every last person who comments asking about the company it’s just too much I’m sorry guys

please note all retaliator bomber ccus are now nulled* list to be updated after IAE
*** I DO NOT CONDUCT ANY TYPE OF MIDDLEMAN OR SALES ON DISCORD, IF SOMEONE SAYS OTHERWISE PLEASE BRING TO MY ATTENTION AND I WILL INFORM THE MODS *** If Interested in any items please PM me with the full description of the items you are interested in. Your Paypal and RSI emails. Transaction will be done through Paypal invoicing. I am usually able to reply immediately, if I do not, then im likely driving or asleep so please be patient and I will get to it as soon as I am up. My time zone is GMT -5. BELOW PRICES SUBJECT TO AVAILABILITY AND CHANGE.

(CCU) - FROM	(CCU) - TO	PROMO	PRICE (INC. PP FEES)
PROWLER	600I EXPLORER	BIS 2953/ 120M INS	20
HORNET GHOST	BALLISTA	120M INS	10
M2 HERCULES	CARRACK	120M INS	68
ECLIPSE	CATERPILLAR	120M INS	25
STARFARER	CATERPILLAR	120M INS	25
RAILEN	CORSAIR	BIS 2953/ 120M INS	25
TERRAPIN	CORSAIR	May include 120M INS	20
DEFENDER	CORSAIR	May include 120M INS	20
NOVA	CUTLASS RED	Career Kit	30
SUPER HORNET HEARTSEEKER	DEFENDER		20
MAKO	FREELANCER	Career Kit	30
STARFARER GEMINI	HULL C		65
PROWLER	HULL C		35
PROWLER	HULL D		50
STARFARER GEMINI	HULL D		115
RECLAIMER	HULL D	120M INS	75
GALAXY	HULL D	120M INS	75
C2 HERCULES	HULL D	120M INS	75
STARFARER GEMINI	MERCHANTMAN		199
ARRASTRA	MERCHANTMAN		52
LIBERATOR	MERCHANTMAN		52
ORION	MERCHANTMAN	Same cost ccu	30
CUTLASS STEEL	MERCURY	BIS 2953/ 120M INS	20
VANGUARD HOPLITE	MERCURY	BIS 2953/ 120M INS	20
HULL D	ORION	120M INS	62
PERSEUS	POLARIS	120M INS	52
HORNET TRACKER	PROSPECTOR	Career Kit	30
BALLISTA	PROSPECTOR	Career Kit	30
C2 HERCULES	PROWLER	120M INS	35
ECLIPSE	REDEEMER	BIS 2953/ 120M INS	30
A1 SPIRIT	SAN'TOK.YAI	120M INS	20
GEMINI	VALKYRIE	Career Kit	50
CONSTELLATION ANDROMEDA	VANGUARD WARDEN		15
PROSPECTOR	VULTURE	Career Kit	30
PROSPECTOR	VULTURE	BIS 2953/ 120M INS	20
RAZOR	VULTURE		10
FREELANCER DUR	VULTURE		30
RAFT	VULTURE	120M INS	35
​

please message me for stock status as i may be out of stock on certain ccus ​ CCULIST H-Z here https://www.reddit.com/Starcitizen_trades/comments/1c1g0m8/wts_prowler_to_hull_d_ccu_50_c2reclaimergalaxy_to/
​ CCU LIST A-G

(CCU) - FROM	(CCU) - TO	MELT VALUE	PRICE (INC. PP FEES)
AVENGER WARLOCK	350R		46
BUCCANEER	350R		20
CENTURION	350R		20
CUTLASS BLACK	350R		20
FREELANCER	350R		20
GLADIUS	350R		41
GLADIUS VALIANT	350R		20
HAWK	350R		30
HERALD	350R		46
HULL A	350R		41
LEGIONNAIRE	350R		10
M50	350R		30
NOMAD	350R		51
NOVA	350R		10
RELIANT MAKO	350R		36
RELIANT SENTINEL	350R		46
STORM	350R		41
STORM AA	350R		30
TALON	350R		15
TALON SHRIKE	350R		15
CONSTELLATION ANDROMEDA	400i		15
CONSTELLATION ANDROMEDA	400I		15
CONSTELLATION TAURUS	400i		56
CONSTELLATION TAURUS	400I		56
DEFENDER	400i		36
DEFENDER	400I		36
HURRICANE	400i		46
HURRICANE	400I		46
RAILEN	400i		30
RAILEN	400I		30
SANTOKYAI	400i		15
SANTOKYAI	400I		15
SCORPIUS	400i		15
SCORPIUS	400I		15
SCORPIUS ANTARES	400i		25
SCORPIUS ANTARES	400I		25
TERRAPIN	400i		36
TERRAPIN	400I		36
VANGUARD HOPLITE	400i		15
VANGUARD HOPLITE	400I		15
VULCAN	400i		56
VULCAN	400I		56
600I TOURING	600I EXPLORER		46
C2 HERCULES	600I EXPLORER		82
CRUCIBLE	600I EXPLORER		134
ENDEAVOR	600I EXPLORER		134
GALAXY	600I EXPLORER		103
GENESIS STARLINER	600I EXPLORER		82
GLAIVE	600I EXPLORER		134
MOLE	600I EXPLORER		171
PROWLER	600I EXPLORER		41
RECLAIMER	600I EXPLORER		82
STARFARER GEMINI	600I EXPLORER		145
VALKYRIE	600I EXPLORER		108
C2 HERCULES	600I TOURING		41
CRUCIBLE	600I TOURING		93
ENDEAVOR	600I TOURING		93
GALAXY	600I TOURING		62
GENESIS STARLINER	600I TOURING		41
GLAIVE	600I TOURING		93
MOLE	600I TOURING		129
RECLAIMER	600I TOURING		41
STARFARER GEMINI	600I TOURING		103
VALKYRIE	600I TOURING		67
ANVIL BALLISTA	A1 SPIRIT		67
ANVIL BALLISTA DUNESTALKER	A1 SPIRIT		67
ANVIL BALLISTA SNOWBLIND	A1 SPIRIT		67
E1 SPIRIT	A1 SPIRIT		56
EXPANSE	A1 SPIRIT		56
F7C-R HORNET TRACKER	A1 SPIRIT		56
FREELANCER DUR	A1 SPIRIT		72
FREELANCER MAX	A1 SPIRIT		56
GLADIATOR	A1 SPIRIT		41
HULL B	A1 SPIRIT		67
KHARTU-AL	A1 SPIRIT		36
MANTIS	A1 SPIRIT		56
PROSPECTOR	A1 SPIRIT		51
RAZOR	A1 SPIRIT		62
RAZOR EX	A1 SPIRIT		51
RAZOR LX	A1 SPIRIT		56
RETALIATOR BASE	A1 SPIRIT		56
SABRE	A1 SPIRIT		36
SRV	A1 SPIRIT		41
ARRASTRA	A2 HERCULES		186
CARRACK	A2 HERCULES		160
CARRACK EXPEDITION	A2 HERCULES		134
CARRACK EXPEDITION W/C8X	A2 HERCULES		114
CARRACK W/C8X	A2 HERCULES		140
HAMMERHEAD	A2 HERCULES		30
HULL D	A2 HERCULES		212
LIBERATOR	A2 HERCULES		186
M2 HERCULES	A2 HERCULES		244
MERCHANTMAN	A2 HERCULES		108
NAUTILUS	A2 HERCULES		30
ODYSSEY	A2 HERCULES		56
ORION	A2 HERCULES		108
PERSEUS	A2 HERCULES		82
400I	APOLLO MEDIVAC		30
400i	APOLLO MEDIVAC		30
APOLLO TRIAGE	APOLLO MEDIVAC		30
ARES INFERNO	APOLLO MEDIVAC		30
ARES ION	APOLLO MEDIVAC		30
CONSTELLATION ANDROMEDA	APOLLO MEDIVAC		41
CONSTELLATION TAURUS	APOLLO MEDIVAC		82
CORSAIR	APOLLO MEDIVAC		30
CUTLASS RED	APOLLO MEDIVAC		150
DEFENDER	APOLLO MEDIVAC		62
HURRICANE	APOLLO MEDIVAC		72
MERCURY STAR RUNNER	APOLLO MEDIVAC		20
RAILEN	APOLLO MEDIVAC		56
SANTOKYAI	APOLLO MEDIVAC		41
SCORPIUS	APOLLO MEDIVAC		41
SCORPIUS ANTARES	APOLLO MEDIVAC		51
TERRAPIN	APOLLO MEDIVAC		62
VANGUARD HOPLITE	APOLLO MEDIVAC		41
VANGUARD WARDEN	APOLLO MEDIVAC		20
VULCAN	APOLLO MEDIVAC		82
CONSTELLATION ANDROMEDA	APOLLO TRIAGE		15
CONSTELLATION TAURUS	APOLLO TRIAGE		56
CUTLASS RED	APOLLO TRIAGE		124
DEFENDER	APOLLO TRIAGE		36
HURRICANE	APOLLO TRIAGE		46
RAILEN	APOLLO TRIAGE		30
SANTOKYAI	APOLLO TRIAGE		15
SCORPIUS	APOLLO TRIAGE		15
SCORPIUS ANTARES	APOLLO TRIAGE		25
TERRAPIN	APOLLO TRIAGE		36
VANGUARD HOPLITE	APOLLO TRIAGE		15
VULCAN	APOLLO TRIAGE		56
CONSTELLATION ANDROMEDA	ARES INFERNO		15
CONSTELLATION TAURUS	ARES INFERNO		56
DEFENDER	ARES INFERNO		36
F7C-M SUPER HORNET	ARES INFERNO		72
F7C-M SUPER HORNET HEARTSEEKER	ARES INFERNO		56
HURRICANE	ARES INFERNO		46
RAILEN	ARES INFERNO		30
SABRE COMET	ARES INFERNO		72
SANTOKYAI	ARES INFERNO		15
SCORPIUS	ARES INFERNO		15
SCORPIUS ANTARES	ARES INFERNO		25
TERRAPIN	ARES INFERNO		36
VANGUARD HOPLITE	ARES INFERNO		15
VULCAN	ARES INFERNO		56
CONSTELLATION ANDROMEDA	ARES ION		15
CONSTELLATION TAURUS	ARES ION		56
DEFENDER	ARES ION		36
F7C-M SUPER HORNET	ARES ION		72
F7C-M SUPER HORNET HEARTSEEKER	ARES ION		56
HURRICANE	ARES ION		46
RAILEN	ARES ION		30
SABRE COMET	ARES ION		72
SANTOKYAI	ARES ION		15
SCORPIUS	ARES ION		15
SCORPIUS ANTARES	ARES ION		25
TERRAPIN	ARES ION		36
VANGUARD HOPLITE	ARES ION		15
VULCAN	ARES ION		56
600I EXPLORER	ARRASTRA		108
600I TOURING	ARRASTRA		150
C2 HERCULES	ARRASTRA		186
CATERPILLAR	ARRASTRA		259
CRUCIBLE	ARRASTRA		238
ENDEAVOR	ARRASTRA		238
GALAXY	ARRASTRA		207
GENESIS STARLINER	ARRASTRA		186
GLAIVE	ARRASTRA		238
HULL C	ARRASTRA		82
HULL D	ARRASTRA		30
M2 HERCULES	ARRASTRA		62
MOLE	ARRASTRA		275
PROWLER	ARRASTRA		145
RECLAIMER	ARRASTRA		186
REDEEMER	ARRASTRA		259
STARFARER GEMINI	ARRASTRA		249
VALKYRIE	ARRASTRA		212
400I	BLADE		30
400i	BLADE		30
APOLLO TRIAGE	BLADE		30
ARES INFERNO	BLADE		30
ARES ION	BLADE		30
CONSTELLATION ANDROMEDA	BLADE		41
CONSTELLATION TAURUS	BLADE		82
CORSAIR	BLADE		30
DEFENDER	BLADE		62
HURRICANE	BLADE		72
MERCURY STAR RUNNER	BLADE		20
RAILEN	BLADE		56
SANTOKYAI	BLADE		41
SCORPIUS	BLADE		41
SCORPIUS ANTARES	BLADE		51
TERRAPIN	BLADE		62
VANGUARD HOPLITE	BLADE		41
VANGUARD WARDEN	BLADE		20
VULCAN	BLADE		82
ARROW	BUCCANEER		41
AVENGER TITAN RENEGADE	BUCCANEER		41
AVENGER WARLOCK	BUCCANEER		30
CYCLONE-AA	BUCCANEER		36
GLADIUS	BUCCANEER		25
HAWK	BUCCANEER		15
HERALD	BUCCANEER		30
HULL A	BUCCANEER		25
M50	BUCCANEER		15
NOMAD	BUCCANEER		36
RELIANT MAKO	BUCCANEER		20
RELIANT SENTINEL	BUCCANEER		30
RELIANT TANA	BUCCANEER		41
STORM	BUCCANEER		25
STORM AA	BUCCANEER		15
SYULEN	BUCCANEER		46
ARROW	C1 SPIRIT		56
AVENGER TITAN RENEGADE	C1 SPIRIT		56
AVENGER WARLOCK	C1 SPIRIT		46
BUCCANEER	C1 SPIRIT		20
CENTURION	C1 SPIRIT		20
CUTLASS BLACK	C1 SPIRIT		20
CYCLONE-AA	C1 SPIRIT		51
FREELANCER	C1 SPIRIT		20
GLADIUS	C1 SPIRIT		41
GLADIUS VALIANT	C1 SPIRIT		20
HAWK	C1 SPIRIT		30
HERALD	C1 SPIRIT		46
HULL A	C1 SPIRIT		41
LEGIONNAIRE	C1 SPIRIT		10
M50	C1 SPIRIT		30
NOMAD	C1 SPIRIT		51
NOVA	C1 SPIRIT		10
RELIANT MAKO	C1 SPIRIT		36
RELIANT SENTINEL	C1 SPIRIT		46
RELIANT TANA	C1 SPIRIT		56
STORM	C1 SPIRIT		41
STORM AA	C1 SPIRIT		30
TALON	C1 SPIRIT		15
TALON SHRIKE	C1 SPIRIT		15
CONSTELLATION AQUILA	C2 HERCULES		93
CRUCIBLE	C2 HERCULES		56
ENDEAVOR	C2 HERCULES		56
GALAXY	C2 HERCULES		25
GLAIVE	C2 HERCULES		56
MOLE	C2 HERCULES		93
STARFARER GEMINI	C2 HERCULES		67
VALKYRIE	C2 HERCULES		30
600I EXPLORER	CARRACK		134
600I TOURING	CARRACK		176
ARRASTRA	CARRACK		30
C2 HERCULES	CARRACK		212
GALAXY	CARRACK		233
GENESIS STARLINER	CARRACK		212
HULL C	CARRACK		108
HULL D	CARRACK		56
LIBERATOR	CARRACK		30
M2 HERCULES	CARRACK		88
PROWLER	CARRACK		171
RECLAIMER	CARRACK		212
400I	CATERPILLAR		88
400i	CATERPILLAR		88
APOLLO MEDIVAC	CATERPILLAR		62
APOLLO TRIAGE	CATERPILLAR		88
ARES INFERNO	CATERPILLAR		88
ARES ION	CATERPILLAR		88
BLADE	CATERPILLAR		62
CONSTELLATION ANDROMEDA	CATERPILLAR		98
CONSTELLATION AQUILA	CATERPILLAR		20
CORSAIR	CATERPILLAR		88
ECLIPSE	CATERPILLAR		36
MERCURY STAR RUNNER	CATERPILLAR		77
MOLE	CATERPILLAR		20
RAILEN	CATERPILLAR		114
RETALIATOR BOMBER	CATERPILLAR		62
SCORPIUS	CATERPILLAR		98
SCORPIUS ANTARES	CATERPILLAR		108
STARFARER	CATERPILLAR		36
VANGUARD HARBINGER	CATERPILLAR		46
VANGUARD HOPLITE	CATERPILLAR		98
VANGUARD SENTINEL	CATERPILLAR		62
VANGUARD WARDEN	CATERPILLAR		77
ARROW	CENTURION		41
AVENGER TITAN RENEGADE	CENTURION		41
AVENGER WARLOCK	CENTURION		30
CYCLONE-AA	CENTURION		36
GLADIUS	CENTURION		25
HAWK	CENTURION		15
HERALD	CENTURION		30
HULL A	CENTURION		25
M50	CENTURION		15
NOMAD	CENTURION		36
RELIANT MAKO	CENTURION		20
RELIANT SENTINEL	CENTURION		30
RELIANT TANA	CENTURION		41
STORM	CENTURION		25
STORM AA	CENTURION		15
SYULEN	CENTURION		46
A1 SPIRIT	CORSAIR		56
CONSTELLATION TAURUS	CORSAIR		56
CUTLASS BLUE	CORSAIR		82
DEFENDER	CORSAIR		36
F7C HORNET WILDFIRE	CORSAIR		82
F7C-M SUPER HORNET	CORSAIR		72
F7C-M SUPER HORNET HEARTSEEKER	CORSAIR		56
FREELANCER MIS	CORSAIR		82
HURRICANE	CORSAIR		46
RAILEN	CORSAIR		30
SABRE COMET	CORSAIR		72
SANTOKYAI	CORSAIR		15
SCORPIUS ANTARES	CORSAIR		25
TERRAPIN	CORSAIR		36
VULCAN	CORSAIR		56
VULTURE	CORSAIR		82
APOLLO MEDIVAC	CRUCIBLE		82
BLADE	CRUCIBLE		82
CATERPILLAR	CRUCIBLE		25
CONSTELLATION AQUILA	CRUCIBLE		41
ECLIPSE	CRUCIBLE		56
MERCURY STAR RUNNER	CRUCIBLE		98
MOLE	CRUCIBLE		41
REDEEMER	CRUCIBLE		25
RETALIATOR BOMBER	CRUCIBLE		82
STARFARER	CRUCIBLE		56
STARFARER GEMINI	CRUCIBLE		15
VANGUARD HARBINGER	CRUCIBLE		67
VANGUARD SENTINEL	CRUCIBLE		82
VANGUARD WARDEN	CRUCIBLE		98
CUTLASS BLACK	CUTLASS BLUE		72
CUTLASS RED	CUTLASS BLUE		46
E1 SPIRIT	CUTLASS BLUE		30
FREELANCER MAX	CUTLASS BLUE		30
GLADIATOR	CUTLASS BLUE		15
KHARTU-AL	CUTLASS BLUE		10
MANTIS	CUTLASS BLUE		30
PROSPECTOR	CUTLASS BLUE		25
RAZOR EX	CUTLASS BLUE		25
RAZOR LX	CUTLASS BLUE		30
RETALIATOR BASE	CUTLASS BLUE		30
SABRE	CUTLASS BLUE		10
SRV	CUTLASS BLUE		15
350R	CUTLASS RED		15
ARROW	CUTLASS RED		67
BUCCANEER	CUTLASS RED		30
C1 SPIRIT	CUTLASS RED		15
CENTURION	CUTLASS RED		30
CUTLASS BLACK	CUTLASS RED		30
FREELANCER	CUTLASS RED		30
GLADIUS	CUTLASS RED		51
GLADIUS VALIANT	CUTLASS RED		30
HAWK	CUTLASS RED		41
HULL A	CUTLASS RED		51
LEGIONNAIRE	CUTLASS RED		20
M50	CUTLASS RED		41
NOVA	CUTLASS RED		20
RAFT	CUTLASS RED		15
TALON	CUTLASS RED		25
TALON SHRIKE	CUTLASS RED		25
A1 SPIRIT	DEFENDER		25
CONSTELLATION TAURUS	DEFENDER		25
CUTLASS BLUE	DEFENDER		51
E1 SPIRIT	DEFENDER		77
F7C HORNET WILDFIRE	DEFENDER		51
F7C-M SUPER HORNET	DEFENDER		41
F7C-M SUPER HORNET HEARTSEEKER	DEFENDER		25
FREELANCER MAX	DEFENDER		77
FREELANCER MIS	DEFENDER		51
GLADIATOR	DEFENDER		62
HURRICANE	DEFENDER		15
KHARTU-AL	DEFENDER		56
PROSPECTOR	DEFENDER		72
RAZOR EX	DEFENDER		72
RAZOR LX	DEFENDER		77
RETALIATOR BASE	DEFENDER		77
SABRE	DEFENDER		56
SABRE COMET	DEFENDER		41
SRV	DEFENDER		62
VULCAN	DEFENDER		25
VULTURE	DEFENDER		51
A1 SPIRIT	ECLIPSE		108
APOLLO MEDIVAC	ECLIPSE		30
BLADE	ECLIPSE		30
MERCURY STAR RUNNER	ECLIPSE		46
RETALIATOR BOMBER	ECLIPSE		30
VANGUARD HARBINGER	ECLIPSE		15
VANGUARD SENTINEL	ECLIPSE		30
VANGUARD WARDEN	ECLIPSE		46
APOLLO MEDIVAC	ENDEAVOR		82
BLADE	ENDEAVOR		82
CATERPILLAR	ENDEAVOR		25
CONSTELLATION AQUILA	ENDEAVOR		41
ECLIPSE	ENDEAVOR		56
MERCURY STAR RUNNER	ENDEAVOR		98
MOLE	ENDEAVOR		41
REDEEMER	ENDEAVOR		25
RETALIATOR BOMBER	ENDEAVOR		82
STARFARER	ENDEAVOR		56
STARFARER GEMINI	ENDEAVOR		15
VANGUARD HARBINGER	ENDEAVOR		67
VANGUARD SENTINEL	ENDEAVOR		82
VANGUARD WARDEN	ENDEAVOR		98
350R	EXPANSE		30
ANVIL BALLISTA	EXPANSE		15
ANVIL BALLISTA DUNESTALKER	EXPANSE		15
ANVIL BALLISTA SNOWBLIND	EXPANSE		15
BUCCANEER	EXPANSE		46
C1 SPIRIT	EXPANSE		30
CENTURION	EXPANSE		46
CUTLASS BLACK	EXPANSE		46
CUTLASS RED	EXPANSE		20
F7C HORNET	EXPANSE		30
F7C-S HORNET GHOST	EXPANSE		15
FREELANCER	EXPANSE		46
FREELANCER DUR	EXPANSE		20
GLADIUS VALIANT	EXPANSE		46
HAWK	EXPANSE		56
HULL B	EXPANSE		15
LEGIONNAIRE	EXPANSE		36
M50	EXPANSE		56
NOVA	EXPANSE		36
RAFT	EXPANSE		30
RAZOR	EXPANSE		10
STORM AA	EXPANSE		56
TALON	EXPANSE		41
TALON SHRIKE	EXPANSE		41
E1 SPIRIT	F7C HORNET WILDFIRE		30
FREELANCER MAX	F7C HORNET WILDFIRE		30
GLADIATOR	F7C HORNET WILDFIRE		15
KHARTU-AL	F7C HORNET WILDFIRE		10
MANTIS	F7C HORNET WILDFIRE		30
PROSPECTOR	F7C HORNET WILDFIRE		25
RAZOR EX	F7C HORNET WILDFIRE		25
RAZOR LX	F7C HORNET WILDFIRE		30
RETALIATOR BASE	F7C HORNET WILDFIRE		30
SABRE	F7C HORNET WILDFIRE		10
SRV	F7C HORNET WILDFIRE		15
CUTLASS BLUE	F7C-M SUPER HORNET		15
E1 SPIRIT	F7C-M SUPER HORNET		41
EXPANSE	F7C-M SUPER HORNET		41
F7C HORNET WILDFIRE	F7C-M SUPER HORNET		15
F7C-R HORNET TRACKER	F7C-M SUPER HORNET		41
FREELANCER MAX	F7C-M SUPER HORNET		41
FREELANCER MIS	F7C-M SUPER HORNET		15
GLADIATOR	F7C-M SUPER HORNET		25
HULL B	F7C-M SUPER HORNET		51
KHARTU-AL	F7C-M SUPER HORNET		20
MANTIS	F7C-M SUPER HORNET		41
PROSPECTOR	F7C-M SUPER HORNET		36
RAZOR	F7C-M SUPER HORNET		46
RAZOR EX	F7C-M SUPER HORNET		36
RAZOR LX	F7C-M SUPER HORNET		41
RETALIATOR BASE	F7C-M SUPER HORNET		41
SABRE	F7C-M SUPER HORNET		20
SRV	F7C-M SUPER HORNET		25
VULTURE	F7C-M SUPER HORNET		15
CUTLASS BLUE	F7C-M SUPER HORNET HEARTSEEKER		30
E1 SPIRIT	F7C-M SUPER HORNET HEARTSEEKER		56
EXPANSE	F7C-M SUPER HORNET HEARTSEEKER		56
F7C HORNET WILDFIRE	F7C-M SUPER HORNET HEARTSEEKER		30
F7C-M SUPER HORNET	F7C-M SUPER HORNET HEARTSEEKER		20
F7C-R HORNET TRACKER	F7C-M SUPER HORNET HEARTSEEKER		56
FREELANCER MAX	F7C-M SUPER HORNET HEARTSEEKER		56
FREELANCER MIS	F7C-M SUPER HORNET HEARTSEEKER		30
GLADIATOR	F7C-M SUPER HORNET HEARTSEEKER		41
HULL B	F7C-M SUPER HORNET HEARTSEEKER		67
KHARTU-AL	F7C-M SUPER HORNET HEARTSEEKER		36
MANTIS	F7C-M SUPER HORNET HEARTSEEKER		56
PROSPECTOR	F7C-M SUPER HORNET HEARTSEEKER		51
RAZOR	F7C-M SUPER HORNET HEARTSEEKER		62
RAZOR EX	F7C-M SUPER HORNET HEARTSEEKER		51
RAZOR LX	F7C-M SUPER HORNET HEARTSEEKER		56
RETALIATOR BASE	F7C-M SUPER HORNET HEARTSEEKER		56
SABRE	F7C-M SUPER HORNET HEARTSEEKER		36
SABRE COMET	F7C-M SUPER HORNET HEARTSEEKER		20
SRV	F7C-M SUPER HORNET HEARTSEEKER		41
VULTURE	F7C-M SUPER HORNET HEARTSEEKER		30
350R	FREELANCER DUR		15
ARROW	FREELANCER DUR		67
BUCCANEER	FREELANCER DUR		30
C1 SPIRIT	FREELANCER DUR		15
CENTURION	FREELANCER DUR		30
CUTLASS BLACK	FREELANCER DUR		30
F7C HORNET	FREELANCER DUR		15
FREELANCER	FREELANCER DUR		30
GLADIUS	FREELANCER DUR		51
GLADIUS VALIANT	FREELANCER DUR		30
HAWK	FREELANCER DUR		41
HULL A	FREELANCER DUR		51
LEGIONNAIRE	FREELANCER DUR		20
M50	FREELANCER DUR		41
NOVA	FREELANCER DUR		20
RAFT	FREELANCER DUR		15
TALON	FREELANCER DUR		25
TALON SHRIKE	FREELANCER DUR		25
350R	FREELANCER MAX		30
ANVIL BALLISTA	FREELANCER MAX		15
ANVIL BALLISTA DUNESTALKER	FREELANCER MAX		15
ANVIL BALLISTA SNOWBLIND	FREELANCER MAX		15
BUCCANEER	FREELANCER MAX		46
C1 SPIRIT	FREELANCER MAX		30
CENTURION	FREELANCER MAX		46
CUTLASS BLACK	FREELANCER MAX		46
CUTLASS RED	FREELANCER MAX		20
F7C HORNET	FREELANCER MAX		30
F7C-S HORNET GHOST	FREELANCER MAX		15
FREELANCER	FREELANCER MAX		46
FREELANCER DUR	FREELANCER MAX		20
GLADIUS VALIANT	FREELANCER MAX		46
HULL B	FREELANCER MAX		15
LEGIONNAIRE	FREELANCER MAX		36
NOVA	FREELANCER MAX		36
RAFT	FREELANCER MAX		30
RAZOR	FREELANCER MAX		10
TALON	FREELANCER MAX		41
TALON SHRIKE	FREELANCER MAX		41
E1 SPIRIT	FREELANCER MIS		30
EXPANSE	FREELANCER MIS		30
F7C-R HORNET TRACKER	FREELANCER MIS		30
FREELANCER MAX	FREELANCER MIS		30
GLADIATOR	FREELANCER MIS		15
HULL B	FREELANCER MIS		41
KHARTU-AL	FREELANCER MIS		10
MANTIS	FREELANCER MIS		30
PROSPECTOR	FREELANCER MIS		25
RAZOR	FREELANCER MIS		36
RAZOR EX	FREELANCER MIS		25
RAZOR LX	FREELANCER MIS		30
RETALIATOR BASE	FREELANCER MIS		30
SABRE	FREELANCER MIS		10
SRV	FREELANCER MIS		15
APOLLO MEDIVAC	GALAXY		114
BLADE	GALAXY		114
CATERPILLAR	GALAXY		56
CONSTELLATION AQUILA	GALAXY		72
CRUCIBLE	GALAXY		36
ECLIPSE	GALAXY		88
ENDEAVOR	GALAXY		36
GLAIVE	GALAXY		36
MERCURY STAR RUNNER	GALAXY		129
MOLE	GALAXY		72
REDEEMER	GALAXY		56
RETALIATOR BOMBER	GALAXY		114
STARFARER	GALAXY		88
STARFARER GEMINI	GALAXY		46
VALKYRIE	GALAXY		10
VANGUARD HARBINGER	GALAXY		98
VANGUARD SENTINEL	GALAXY		114
VANGUARD WARDEN	GALAXY		129
CONSTELLATION AQUILA	GENESIS STARLINER		93
CRUCIBLE	GENESIS STARLINER		56
ENDEAVOR	GENESIS STARLINER		56
GALAXY	GENESIS STARLINER		25
GLAIVE	GENESIS STARLINER		56
MOLE	GENESIS STARLINER		93
STARFARER GEMINI	GENESIS STARLINER		67
VALKYRIE	GENESIS STARLINER		30
ANVIL BALLISTA	GLADIATOR		30
ANVIL BALLISTA DUNESTALKER	GLADIATOR		30
ANVIL BALLISTA SNOWBLIND	GLADIATOR		30
CUTLASS RED	GLADIATOR		36
E1 SPIRIT	GLADIATOR		20
EXPANSE	GLADIATOR		20
F7C-R HORNET TRACKER	GLADIATOR		20
FREELANCER DUR	GLADIATOR		36
FREELANCER MAX	GLADIATOR		20
HULL B	GLADIATOR		30
MANTIS	GLADIATOR		20
PROSPECTOR	GLADIATOR		15
RAZOR	GLADIATOR		25
RAZOR EX	GLADIATOR		15
RAZOR LX	GLADIATOR		20
RETALIATOR BASE	GLADIATOR		20
ARROW	GLADIUS VALIANT		41
AVENGER TITAN RENEGADE	GLADIUS VALIANT		41
AVENGER WARLOCK	GLADIUS VALIANT		30
CYCLONE-AA	GLADIUS VALIANT		36
GLADIUS	GLADIUS VALIANT		25
HAWK	GLADIUS VALIANT		15
HERALD	GLADIUS VALIANT		30
HULL A	GLADIUS VALIANT		25
M50	GLADIUS VALIANT		15
NOMAD	GLADIUS VALIANT		36
RELIANT MAKO	GLADIUS VALIANT		20
RELIANT SENTINEL	GLADIUS VALIANT		30
RELIANT TANA	GLADIUS VALIANT		41
STORM	GLADIUS VALIANT		25
STORM AA	GLADIUS VALIANT		15
SYULEN	GLADIUS VALIANT		46
CATERPILLAR	GLAIVE		61
CONSTELLATION AQUILA	GLAIVE		77
MOLE	GLAIVE		77
REDEEMER	GLAIVE		61
STARFARER GEMINI	GLAIVE		51
​

Job Title	Company	Salary	Full Remote in...
SAP Support Consultant	Triathlon Holding GmbH	-	Germany
(Senior) Software Engineer Java & Cloud (m/w/d)	Datev	-	Germany
Post-Sales Machine Learning Engineer, Customer Success	Wandb	-	EMEA
Amazon Associate	Darkroom	-	Americas
Marketing Executive	RobotZebra	-	UK
Account Executive	Deepgram	-	USA
Account Executive	Trust Keith	-	UK
Group Technical Product Manager	Renaissance	-	USA
IT Project Manager	Fortis Games	-	Portugal
People Operations Analyst	Foodsmart	-	USA
QA Engineer	Tinybeans	-	LATAM, USA, Canada
Web Security Developer	TEC Group Inc.	-	USA
Salesforce Administrator	Buildertrend	-	USA
Senior Java Developer	CloudHire	-	USA
Customer Success Manager	Helium 10	-	USA

Currently there are 306,186,849 shares of common stock outstanding. Last week, the posted snapshot from Bloomberg indicated that in sum about 1.2 million shares have been bought by GameStop under rule 10b-18. This would decrease the publicly available share count to approximately 305 million. GameStop have now declared they may at any time issue an additional 45 million common shares and 5 million preferred shares.
Tinfoil Prediction: they will issue 10 million common shares at market price and raise the share count (ex counterfeits) to 315 million. That number is divisible by 7. After issuance of those 10 million common shares, they will issue one (fraction of a) preferred share for every 7 common shares (741). The preferred shares will be issued via an issuing agent which happens to be Computershare. Accounts held with the transfer agent, which also happens to be computershare, will receive the preferred shares directly and the remaining 60-70% of preferred shares will be dumped on the depo (DTC) or the brokers, who then can try to distribute them (lol) or rather fight for them because: Holders of shares of Common Stock held in “street name” through a brokerage account, bank or other nominee will not receive physical rights certificates and must instruct their broker, bank or other nominee whether to exercise Subscription Rights on their behalf.
The clue is in the name and preferred shares have some preferable status, such as regular dividends etc. In this particular case, they may have the non-transferable and non (cash-)substitutable right attached to a subscription of common shares, meaning the right to acquire common shares at a predefined price such as for a discount to the market price. This makes preferred shares inherently more valuable than common shares (take a look at BNED this week and their filing on 15 May 2024). Consequently, market participants may compete to receive the preferred shares and may pay a premium for common shares prior to issuance of preferred shares or recall the ones which may have been lent. This may put shorts under water. GameStop may use the proceeds from issuing 10 million shares to strengthen the balance sheet. GameStop might also incentivize holders of preferred stock further by issuing other benefits such as NFT divis, wu tang audio etc. However, the proceeds may also be used to finance equity investments in compliance with GameStops investment policy or repurchase of their common stock. The continuation of such repurchases under rule 10b-18 may be particularly interesting at the time due to the volume restriction based on average trading volume of the preceding four weeks at the time of a buyback under this rule. Currently, the 10 day trading volume is 73.1 million shares (according to Schwab). This is another factor that might put shorts under water. To spell it out clearly: given the action of the last week, GameStop could currently raise capital (but don’t need to) and repurchase a fat amount of its own common stock on the free market and yet remain in compliance with the safe harbor rule.
Substantial rises in the stock price could then incentive GameStop to issue more of their remaining 35 million shares of common stock to procure working capital or capital for future buybacks. However, a decreasing stock price could incentivize GameStop to issue shares and then repurchase them at a lower price, continuously decreasing the share count and thus applying upwards pressure on the price in the long run. Holders of common stock AND preferred stock need not worry about this since proceeds from the business activities could then be rerouted via preferred shares. In the end, every market participant had a right and chance to gain his preferred shares, right ;)
Edit: fractionalizability of preferred shares as defined in the recently published S3 document.
Edit 2: Relevant Barnes filing:
BASKING RIDGE, N.J.--(BUSINESS WIRE)--May 15, 2024--Barnes & Noble Education, Inc. (NYSE: BNED) (“BNED” or the “Company”), a leading solutions provider for the education industry, announced today that its registration statement for its fully backstopped $45 million equity rights offering (the “Rights Offering”), was declared effective by the Securities and Exchange Commission (“SEC”) on May 14, 2024.
The Rights Offering is one of the previously announced proposed transactions (the “Transactions”) contemplated by the Company’s definitive agreement with Immersion Corporation (NASDAQ: IMMR) (“Immersion”), and certain of the Company’s existing shareholders and strategic partners, that will enable the Company to substantially deleverage its balance sheet, strategically invest in innovation and operate from a position of strength. The Transactions remain subject to shareholder approval and other closing conditions.
Upon closing of the Transactions, which is currently expected to occur in June 2024:
BNED will receive gross proceeds of $95 million of new equity capital through the Rights Offering and a $50 million new equity investment led by Immersion; the Transactions are expected to infuse approximately $75 million of net cash proceeds after transaction costs;
The Company’s existing second lien lenders will convert approximately $34 million of outstanding principal and any accrued and unpaid interest into BNED Common Stock; and
The Company has received commitments to refinance its existing asset backed loan facility, pursuant to an agreement with its first lien holders, providing the Company with access to a $325 million facility (the “ABL Facility”) maturing in 2028. The refinanced ABL Facility will meaningfully enhance BNED’s financial flexibility and reduce its annual interest expense.
Through the Rights Offering, BNED will issue 900,000,000 shares of its common stock, par value $0.01 per share (the “Common Stock”) at a cash subscription price (the “Subscription Price”) of $0.05 per share. In the Rights Offering, BNED will distribute to each holder of record of its Common Stock on May 14, 2024 (the “Record Date”) one non-transferable subscription right (each, a “Subscription Right”) for every share of Common Stock owned by such holder on the Record Date, and each Subscription Right will entitle the holder to purchase 17 shares of Common Stock. Each holder that fully exercises their Subscription Rights will be entitled to Over-Subscription Rights to subscribe for additional shares of Common Stock that remain unsubscribed as a result of any unexercised Subscription Rights, which allows such holder to subscribe for additional shares of Common Stock up to the number of shares purchased under such holder’s basic Subscription Right at $0.05 per share.
If any Subscription Rights remain unexercised upon the expiration of the Rights Offering after accounting for all Over-Subscription Rights exercised, the standby purchasers led by Immersion, Outerbridge Capital Management, LLC and Selz Family 2011 Trust will collectively purchase, at the Subscription Price, up to $45 million in shares of Common Stock not subscribed for by the Company’s stockholders.
The Company will not issue fractional shares in the Rights Offering or cash in lieu of fractional shares of Common Stock. Any fractional shares of Common Stock that would be created by an exercise of the Subscription Rights will be rounded to the nearest whole share.
The Company expects that the net proceeds of the offering will be used to pay expenses in connection with the Transactions and reduce the balance under the Company’s ABL Facility.
The Company expects that Computershare Trust Company N.A., the subscription agent for the Rights Offering, will mail rights certificates and a copy of the prospectus for the Rights Offering to holders of record of Common Stock as of the Record Date beginning on or about May 15, 2024. Holders of shares of Common Stock held in “street name” through a brokerage account, bank or other nominee will not receive physical rights certificates and must instruct their broker, bank or other nominee whether to exercise Subscription Rights on their behalf.
The subscription period will expire at 5:00 p.m., Eastern Time, on June 5, 2024. However, the Company may extend the period for exercising the Subscription Rights. Subscription Rights that are not exercised by the expiration date of the Rights Offering will expire and will have no value.
The shares of Common Stock to be issued upon exercise of the Subscription Rights will be listed for trading on the New York Stock Exchange (“NYSE”) under the symbol “BNED.” The Subscription Rights are non-transferable and the Company will not be listing the Subscription Rights on the NYSE or any other national securities exchange.
Neither the Company nor its Board of Directors has made or will make any recommendation to holders regarding the exercise of Subscription Rights. Holders should make an independent investment decision about whether or not to exercise their Subscription Rights based on their own assessment of the Company’s business, the Rights Offering and the other Transactions.
Questions about the Rights Offering or requests for a copy of the prospectus related to the Rights Offering may be directed to the Information Agent, Innisfree M&A Incorporated, at (877) 800-5185. (Banks & Brokers may call collect: (212) 750-5833.
Other Important Information
The issuance and sale of shares of Common Stock pursuant to the Rights Offering is subject to, among other things, the approval of our stockholders at a special meeting (the “Special Meeting”) to be held on June 5, 2024. If the issuance and sale of our Common Stock pursuant to the Rights Offering is not approved at the Special Meeting, then the Rights Offering will be cancelled. The Rights Offering is being made pursuant to the Company’s registration statement on Form S-1 (File No. 333-278799), which was declared effective on May 14, 2024. The Company reserves the right to cancel or terminate the Rights Offering at any time. This press release does not constitute an offer to sell or the solicitation of an offer to buy any Subscription Rights or any other securities to be issued in the Rights Offering or any related transactions, nor shall there be any offer, solicitation or sale of Subscription Rights or any other securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
Edit 3: Barnes pumped 150% on Friday.

Job Title	Company	Salary	Full Remote in...
[Full Stack Software Engineer	Leading ESG Focused Renewable Energy Firm	Fully Remote (occasional travel)](https://remotive.com/remote-jobs/software-dev/full-stack-software-engineer-leading-esg-focused-renewable-energy-firm-fully-remote-occasional-travel-1913570)	Selby Jennings
CyberArk Engineer	TalentBurst, an Inc 5000 company	-	USA
FIS Application Suite Expert	Darwin Recruitment	-	Germany
Senior IAM Engineer	Converge Technology Solutions	-	USA
Lead Backend Engineer (Nodejs) - FS	Yassir	-	Worldwide
SLED Portfolio Solutions Engineer	NICE	-	USA
Senior Product Manager	Altium®	-	USA
Digital Insurance Project Manager	CoverGo	-	India
Senior Finance Manager	Vendavo	-	USA
Content Writer	americanbridgepac	-	USA
Sales Field and Customer Management Employee - Remote	Tyczka Group	-	Germany

Noticed this on my copy of L.A., wondering if anyone had any info.

The global rotator cuff repair devices market is poised to expand at a substantial Compound Annual Growth Rate (CAGR) of over 5% from 2024 to 2030. This growth is primarily propelled by the rapid increase in the geriatric population worldwide. According to the United Nations, the demographic of individuals aged over 80 years is anticipated to triple by 2025, reaching 425 million by 2020 from 137 million in 2017. This demographic shift underscores the growing demand for healthcare solutions targeting age-related conditions, including rotator cuff injuries. Furthermore, the escalating demand for minimally invasive surgical procedures across the globe is expected to further drive market growth, as patients and healthcare providers increasingly prefer less invasive treatment options for improved recovery times and reduced post-operative complications.
To know more about this study, request a free sample report @ https://www.researchcorridor.com/request-sample/?id=145787
Market Trends:
Advancements in Surgical Techniques: Technological advancements and innovations in surgical techniques, such as arthroscopic procedures and tendon-to-bone repair methods, are driving the development of more effective and minimally invasive approaches to rotator cuff repair. These advancements aim to improve patient outcomes, reduce recovery times, and minimize post-operative complications.
Shift towards Biocompatible Materials: There is a growing trend towards the use of biocompatible materials in rotator cuff repair devices, such as bioabsorbable anchors and sutures. These materials minimize the risk of adverse reactions and inflammation, promote tissue healing, and ultimately enhance the long-term success of rotator cuff repairs.
Personalized Medicine and Patient-Specific Implants: With the increasing focus on personalized medicine, there is a growing interest in patient-specific implants and customized treatment plans for rotator cuff injuries. Advances in imaging technology and 3D printing enable the creation of implants tailored to individual patient anatomy, optimizing surgical outcomes and improving patient satisfaction.
Rise in Sports-Related Injuries: Sports-related injuries, including rotator cuff tears, are on the rise due to increasing participation in sports and physical activities. This trend is driving the demand for innovative rotator cuff repair devices designed to address the unique biomechanical challenges and rehabilitation needs of athletes and active individuals.
Integration of Digital Health Technologies: The integration of digital health technologies, such as wearable sensors, mobile apps, and telemedicine platforms, is transforming the management of rotator cuff injuries. These technologies enable remote monitoring of patient progress, real-time feedback during rehabilitation, and virtual consultations with healthcare providers, improving overall patient care and outcomes.
Market Opportunities:
The rotator cuff repair devices market presents several opportunities for growth and innovation. With the increasing prevalence of rotator cuff injuries due to factors such as aging populations, sports-related activities, and occupational hazards, there is a growing demand for advanced treatment options and surgical interventions. Manufacturers have the opportunity to develop and commercialize innovative rotator cuff repair devices that address unmet clinical needs, improve surgical outcomes, and enhance patient satisfaction. Additionally, the shift towards minimally invasive surgical techniques and outpatient procedures presents opportunities for the development of specialized devices optimized for less invasive approaches. Furthermore, the integration of digital health technologies and regenerative medicine approaches offers avenues for developing adjunctive therapies and complementary solutions to enhance the efficacy and durability of rotator cuff repairs.
According to the recent report published by RC Market Analytics, the Global Rotator Cuff Repair Devices Market is expected to provide sustainable growth opportunities during the forecast period from 2024 to 2030. This latest industry research study analyzes the rotator cuff repair devices market by various product segments, applications, regions and countries while assessing regional performances of numerous leading market participants. The report offers a holistic view of the rotator cuff repair devices industry encompassing numerous stakeholders including raw material suppliers, providers, distributors, consumers and government agencies, among others. Furthermore, the report includes detailed quantitative and qualitative analysis of the global market considering market history, product development, regional dynamics, competitive landscape, and key success factors (KSFs) in the industry.
Browse the Full Report Discretion @ https://www.researchcorridor.com/rotator-cuff-repair-devices-market/
Geographically, the rotator cuff repair devices market report comprises dedicated sections centering on the regional market revenue and trends. The rotator cuff repair devices market has been segmented on the basis of geographic regions into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Rotator cuff repair devices market estimates have also been provided for the historical years 2020 to 2023 along with forecast for the period from 2024 - 2030.The report includes a deep-dive analysis of key countries including the U.S., Canada, the U.K., Germany, France, Italy, China, Japan, India, Australia, Mexico, Brazil and South Africa, among others. Thereby, the report identifies unique growth opportunities across the world based on trends occurring in various developed and developing economies.
The Rotator Cuff Repair Devices Market Segmentation:
By Product Type:

• Suture Anchor-based
• Anchor Free

By Usability:

• Reusable
• Disposable

By End-User:

• Hospitals
• Outpatient Centers

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key players in the global rotator cuff repair devices market include MinInvasive Ltd, NCS Lab Srl, Arthrex, Inc., Stryker Corporation, and Johnson & Johnson. These companies employ strategies such as expansion, new investments, service innovation, and collaboration to navigate the market landscape. By expanding into new geographic regions and engaging in strategic acquisitions, they aim to establish a competitive advantage and leverage synergies for mutual growth and success.
To know more about this study, request a free sample report @ https://www.researchcorridor.com/request-sample/?id=145787
Key Questions Answered by Rotator Cuff Repair Devices Market Report:

• Product popularity and adoption based on various country-level dynamics
• Regional presence and product development for leading market participants
• Market forecasts and trend analysis based on ongoing investments and economic growth in key countries
• Competitive landscape based on revenue, product offerings, years of presence, number of employees and market concentration, among others
• Various industry models such as SWOT analysis, Pestle Analysis, Porter’s Five Force model, Value Chain Analysis pertaining to Rotator Cuff Repair Devices market
• Analysis of the key factors driving and restraining the growth of the global, regional and country-level markets from 2020-2030

About Us:RC Market Analytics is a global market research firm. Our insightful analysis is focused on developed and emerging markets. We identify trends and forecast markets with a view to aid businesses identify market opportunities to optimize strategies. Our expert’s team of analysts’ provides enterprises with strategic insights. RC Market Analytics works to help enterprises grow through strategic insights and actionable solutions. Feel free to contact us for any report customization at sales@researchcorridor.com.
Media Contact:
Company Name: RC Market Analytics Pvt. Ltd. Contact Person: Vijendra Singh Email: sales@researchcorridor.com Visit us: https://www.researchcorridor.com/

The global albendazole market is expected to witness a noteworthy Compound Annual Growth Rate (CAGR) of 3.6% during the forecast period reaching an estimated value of 781 million by 2027. This growth is primarily driven by a significant rise in soil-transmitted helminth infections worldwide. Additionally, the effective implementation of treatment guidelines for parasitic infections by healthcare agencies globally further amplifies the growth of the albendazole market.
To know more about this study, request a free sample report @ https://www.researchcorridor.com/request-sample/?id=86884
Market Trends:
Rising Prevalence of Soil-Transmitted Helminth Infections: Soil-transmitted helminth infections, such as roundworm, hookworm, and whipworm infections, continue to be a significant public health concern, particularly in low- and middle-income countries. The increasing prevalence of these infections is driving the demand for albendazole, which is widely used for the treatment of parasitic worm infestations.
Expansion of Mass Drug Administration Programs: Mass drug administration (MDA) programs, aimed at treating entire communities or populations at risk of parasitic infections, are being expanded in many regions. Albendazole is commonly used in MDA programs targeting soil-transmitted helminth infections, contributing to its steady demand and market growth.
Growing Awareness and Screening Initiatives: Increasing awareness about parasitic infections and the importance of regular deworming treatments is leading to greater screening and treatment initiatives in both healthcare facilities and community settings. This trend is expected to drive the demand for albendazole as a key treatment option for parasitic infections.
Preference for Oral Anthelmintic Drugs: Albendazole's oral formulation offers convenience and ease of administration compared to other anthelmintic drugs, particularly in mass treatment programs and pediatric populations. This preference for oral medications contributes to the sustained demand for albendazole in the treatment of parasitic infections.
Emergence of Drug Resistance: Despite its efficacy, there have been reports of emerging drug resistance to albendazole in certain parasitic populations. This trend highlights the need for continued surveillance, monitoring, and research to address drug resistance and ensure the ongoing effectiveness of albendazole in combating parasitic infections.
Market Opportunities:
The albendazole market presents several opportunities for growth and advancement. With the persistent prevalence of soil-transmitted helminth infections globally, there is a significant opportunity for manufacturers and healthcare providers to expand the reach of albendazole-based treatment interventions, particularly in regions with high disease burden. The expansion of mass drug administration programs and increasing awareness about parasitic infections create avenues for market penetration and increased demand for albendazole. Moreover, ongoing research and development initiatives aimed at developing improved formulations, addressing drug resistance, and enhancing patient compliance offer opportunities for innovation and product differentiation. Additionally, collaborations between governments, international organizations, and pharmaceutical companies to improve access to essential medicines, including albendazole, in low-resource settings present opportunities for market expansion and social impact.
According to the recent report published by RC Market Analytics, the Global Albendazole Market is expected to provide sustainable growth opportunities during the forecast period from 2024 to 2030. This latest industry research study analyzes the albendazole market by various product segments, applications, regions and countries while assessing regional performances of numerous leading market participants. The report offers a holistic view of the albendazole industry encompassing numerous stakeholders including raw material suppliers, providers, distributors, consumers and government agencies, among others. Furthermore, the report includes detailed quantitative and qualitative analysis of the global market considering market history, product development, regional dynamics, competitive landscape, and key success factors (KSFs) in the industry.
Browse the Full Report Discretion @ https://www.researchcorridor.com/albendazole-market/
Geographically, the albendazole market report comprises dedicated sections centering on the regional market revenue and trends. The albendazole market has been segmented on the basis of geographic regions into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Albendazole market estimates have also been provided for the historical years 2020 to 2023 along with forecast for the period from 2024 - 2030.The report includes a deep-dive analysis of key countries including the U.S., Canada, the U.K., Germany, France, Italy, China, Japan, India, Australia, Mexico, Brazil and South Africa, among others. Thereby, the report identifies unique growth opportunities across the world based on trends occurring in various developed and developing economies.
The Albendazole Market Segmentation:
By Clinical Application:

• Soil-transmitted Helminths
• Schistosomiasis
• Others

By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Others

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key players in the global albendazole market include Cadila Healthcare Limited, Actavis Pharma, Inc., Cipla Limited, GlaxoSmithKline Plc., and Mankind Pharma. These companies are strategically navigating the market landscape through expansion, new investments, service innovations, and collaborative ventures. By expanding into new geographic regions and engaging in strategic acquisitions, they aim to establish a competitive advantage and leverage synergies for mutual growth and success.
To know more about this study, request a free sample report @ https://www.researchcorridor.com/request-sample/?id=86884
Key Questions Answered by Albendazole Market Report:

• Product popularity and adoption based on various country-level dynamics
• Regional presence and product development for leading market participants
• Market forecasts and trend analysis based on ongoing investments and economic growth in key countries
• Competitive landscape based on revenue, product offerings, years of presence, number of employees and market concentration, among others
• Various industry models such as SWOT analysis, Pestle Analysis, Porter’s Five Force model, Value Chain Analysis pertaining to Albendazole market
• Analysis of the key factors driving and restraining the growth of the global, regional and country-level markets from 2020-2030

About Us:RC Market Analytics is a global market research firm. Our insightful analysis is focused on developed and emerging markets. We identify trends and forecast markets with a view to aid businesses identify market opportunities to optimize strategies. Our expert’s team of analysts’ provides enterprises with strategic insights. RC Market Analytics works to help enterprises grow through strategic insights and actionable solutions. Feel free to contact us for any report customization at sales@researchcorridor.com.
Media Contact:
Company Name: RC Market Analytics Pvt. Ltd. Contact Person: Vijendra Singh Email: sales@researchcorridor.com Visit us: https://www.researchcorridor.com/

The global flat glass coatings market is poised to achieve a substantial Compound Annual Growth Rate (CAGR) of over 20% from 2024 to 2030. This growth is primarily propelled by the rapid expansion of infrastructural activities in developing economies. The escalating adoption of glass in building construction for residential and commercial purposes is anticipated to further bolster market growth throughout the forecast period. Additionally, the swift pace of urbanization and augmented expenditure on decoration and architectural design in emerging economies are significant contributors expected to drive market expansion.
To know more about this study, request a free sample report @ https://www.researchcorridor.com/request-sample/?id=130995
Market Trends:
Growing Demand for Energy-Efficient Coatings: There is a rising demand for energy-efficient coatings that enhance the thermal insulation properties of flat glass, reducing heat transfer and improving energy efficiency in buildings. Manufacturers are developing advanced low-emissivity (Low-E) coatings and solar control coatings to meet the increasing demand for sustainable building solutions.
Focus on Sustainable and Environmentally Friendly Coatings: With increasing environmental awareness, there is a growing emphasis on sustainable and environmentally friendly coating solutions. Manufacturers are developing water-based and solvent-free coatings with reduced volatile organic compound (VOC) emissions to meet regulatory requirements and cater to environmentally conscious consumers.
Advancements in Self-Cleaning Coatings: Self-cleaning coatings for flat glass surfaces are gaining popularity due to their ability to repel dirt, dust, and water, reducing the need for frequent cleaning and maintenance. Innovations in nano-coating technologies are driving the development of highly effective self-cleaning coatings with long-lasting performance.
Emergence of Anti-Reflective Coatings: Anti-reflective coatings are becoming increasingly prevalent in applications where glare reduction and enhanced visibility are desired, such as architectural glass, automotive windshields, and electronic displays. The development of advanced anti-reflective coatings with improved durability and optical clarity is a key trend in the flat glass coating market.
Demand for Decorative and Aesthetic Coatings: There is a growing demand for decorative and aesthetic coatings that enhance the visual appeal of flat glass surfaces in architectural and interior design applications. Manufacturers are offering a wide range of decorative coatings, including tinted, frosted, patterned, and textured coatings, to meet diverse aesthetic preferences and design requirements.
Market Opportunities:
The flat glass coating market presents several opportunities for growth and innovation. With the increasing focus on energy efficiency and sustainability in the construction industry, there is a growing demand for advanced coatings that improve the thermal performance of flat glass windows and facades. Manufacturers have the opportunity to develop innovative low-emissivity (Low-E) and solar control coatings that meet stringent energy efficiency standards and contribute to green building certifications. Additionally, the rising adoption of smart coatings with self-cleaning, anti-fogging, and anti-microbial properties presents opportunities for manufacturers to differentiate their products and cater to evolving customer needs. Moreover, the expanding use of decorative and aesthetic coatings in architectural and interior design applications offers opportunities for the development of customized coating solutions that enhance the visual appeal of flat glass surfaces.
According to the recent report published by RC Market Analytics, the Global Flat Glass Coating Market is expected to provide sustainable growth opportunities during the forecast period from 2024 to 2030. This latest industry research study analyzes the flat glass coating market by various product segments, applications, regions and countries while assessing regional performances of numerous leading market participants. The report offers a holistic view of the flat glass coating industry encompassing numerous stakeholders including raw material suppliers, providers, distributors, consumers and government agencies, among others. Furthermore, the report includes detailed quantitative and qualitative analysis of the global market considering market history, product development, regional dynamics, competitive landscape, and key success factors (KSFs) in the industry.
Browse the Full Report Discretion @ https://www.researchcorridor.com/flat-glass-coating-market/
Geographically, the flat glass coating market report comprises dedicated sections centering on the regional market revenue and trends. The flat glass coating market has been segmented on the basis of geographic regions into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Flat glass coating market estimates have also been provided for the historical years 2020 to 2023 along with forecast for the period from 2024 - 2030.The report includes a deep-dive analysis of key countries including the U.S., Canada, the U.K., Germany, France, Italy, China, Japan, India, Australia, Mexico, Brazil and South Africa, among others. Thereby, the report identifies unique growth opportunities across the world based on trends occurring in various developed and developing economies.
The Flat Glass Coating Market Segmentation:
By Resin:

• Polyurethane (PU)
• Acrylic
• Epoxy
• Others

By Technology:

• Solvent-based
• Water-based
• Nano-based

By Application:

• Solar Power
• Mirror
• Architectural
• Automotive & Transportation
• Other

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key players in the global flat glass coatings market include Arkema, Inc., Fenzi Spa, Ferro Corp., Hesse Gmbh & Co. KG, and The Sherwin-Williams Company. These companies are pursuing market growth through strategies such as expansion, new investments, service innovation, and collaborative ventures. By expanding into new geographic regions and engaging in strategic acquisitions, they aim to establish a competitive advantage and leverage synergies for mutual benefit.
To know more about this study, request a free sample report @ https://www.researchcorridor.com/request-sample/?id=130995
Key Questions Answered by Flat Glass Coating Market Report:

• Product popularity and adoption based on various country-level dynamics
• Regional presence and product development for leading market participants
• Market forecasts and trend analysis based on ongoing investments and economic growth in key countries
• Competitive landscape based on revenue, product offerings, years of presence, number of employees and market concentration, among others
• Various industry models such as SWOT analysis, Pestle Analysis, Porter’s Five Force model, Value Chain Analysis pertaining to Flat Glass Coating market
• Analysis of the key factors driving and restraining the growth of the global, regional and country-level markets from 2020-2030

About Us:RC Market Analytics is a global market research firm. Our insightful analysis is focused on developed and emerging markets. We identify trends and forecast markets with a view to aid businesses identify market opportunities to optimize strategies. Our expert’s team of analysts’ provides enterprises with strategic insights. RC Market Analytics works to help enterprises grow through strategic insights and actionable solutions. Feel free to contact us for any report customization at sales@researchcorridor.com.
Media Contact:
Company Name: RC Market Analytics Pvt. Ltd. Contact Person: Vijendra Singh Email: sales@researchcorridor.com Visit us: https://www.researchcorridor.com/

5/15/24 co CEO Fortress announces closure of Fortress Mgt buyback from Softbank. Now Fortress is ready to roll at Novation Co NOVCQ a public company hidden by SEC Rule 15c2-11 with partners co investors Mass Mutual & sub Barings aka Babson Capital, Jefferies $JEF & White Mountain’s Capital $WTM & NOVCQ Board of Directors Barry Igdaloff’s Howard Amster & Whitney Tilson, Chuck Gillman, Jeffrey Eberwein, David Pointer, Tim Eriksen, Lee Keddie & Robert Pearse. These people are all connected and their 3 NOVCQ restructuring are all connected and advised by 3 third party professionals TPP Boulay Group, Olshan Law, Shapiro Sher. These TPP are no different then Sullivan Cromwell aiding the FTX scheme.
https://www.pionline.com/alternatives/fortress-mubadala-complete-acquisition-fortress-investment-group
World Leading Investors Fortress, EJF Capital aka FBR, MassMutual Barings, Jefferies, White Mountains Capital $WTM are about to create BILLIONS in Capital plus Hundreds of Millions in Cash Flow every year. This is how Whitney Tilson's pals Chuck Gillman, Jeff Eberwein and their co-investors siege control of Novation Companies $NOVC. Use SEC Rule 15C(2)-11 to drive share price down, while taking 16M or 10% of stock at pennies as partial board compensation. Equipped with 40M common shares of NOVCQ they are ready to make Billions plus Create $100Ms every year in cash flow in dividends/Mgt Fees. They have a world class roster of investors supporting them including; MassMutual Barings/Jefferies 40M and Fortress/EJF Capital 31.3M NOVCQ common shares (EJF formerly FBR is owned by White Mountains Capital $WTM). Fortress/EJF Capital also own $NOVCQ only Sr Debt to exit their 1st Ch 11 MD and was used in 2nd Ch 11 in DE filed 8/13/2024. Fortress/EJF invested a few thousand dollars in Off Balance Sheet entities Taberna Trups CDOs I & II/Kodiak CDO I, that hold NOVCQ only Sr Debt. After the 1st Ch 11 NOVCQ Board of Director Barry Igdaloff, Howard Amster hands Fortress/EJF Capital 31M shares allocated by Board at zero basis. This proves NOVCQ Board of Directors was not independent from Sr Debt Holders Fortress/EJF Capital. Sr Debt was a ruse including its use in DE Ch 11. DE Ch 11 was carefully crafted to provide short sellers a way to take tax free gains. The Board with little cash invested holds control of this former NYSE MREIT Novastar Financial Inc. traded under MREIT NYSE Exemption $NFI now Novation $NOVCQ.
Per WSJ Wesley Edens of Fortress is the new MREIT Subprime KING after restructuring Mr. Cooper $COOP and OMF One Main aka LEAF AIG and Citi Bank Subprime CaPersonal Lending unit, and RITM/NRZ and Dynex Capital DX. Manny Friedman Founder of EJF Capital formerly FBR Friedman, Billings Ramsey, is regarded as a leading MREIT expert. They control Novation Companies Inc. NOVCQ thanks to $NOVCQ Board of Directors who they have a past relationship. They renamed Novastar Financial Inc. former traded NSYE as $NFI to Novation Companies, which owns MREIT Novastar Financial Inc., renamed Novastar Mortgage inside 2nd Ch 11 in DE. A new 8-Member Board is waiting in the wings with new name/symbol. I have been told they have big plans for NOVCQ only operating unit http://healthcare-staffing.com HCS which owns and conceals Medmasa http://medmasa.com
I believe they will merge HCS/Medmasa with Jeff Eberwein Hudson Global $HSON to create quarter billion tax free BPO public company. Jeffrey Eberwein is the former NOVCQ COB/CEO that managed 1st Ch 11 in MD with Shapiro Sher. Eberwein is now COB/CEO of Hudson Global $HSON. This merger will monetize NOVCQ $730M NOLs just like both CH 11 the 1st in Maryland, MD & 2nd or last in Delaware, DE. Both used Sr Debt as ruse to execute both Ch 11s which have gone to great length to save NOVCQ $730M NOLs. 2022 NOVCQ triggered SEC Rule 15c(2)-11 which allows NOVCQ to remain public but conceals who is buying NOVCQ as only Expert Investors can accumulate NOVCQ like Putnam Inv. Goldman Sachs, Blackrock & David Dreman of Dreman Value Mgt. and Thomas Akin Talkot Capital fund owns 1.9M common. This SEC Rule is postured as way for small public company to remain public and not have the cost burden of SEC filings. What it really does is stops Retail bid/ask and allows Expert Investors in the know to front run a public company before rolling out true reorganization plans.
They are ready to change Novation Co $NOVCQ name and brand so as to eliminate any reference to the prior board or brand. This is how they roll. I believe they will present the new name/symbol and 8-Member Board comprised of Fortress, EJF Capital aka FBR people once Fortress Management close Softbank SALE of Fortress (DONE See Top 5/15/24 Announcement) to them and Mubadala Investment Company ex Fortress executive Rajeev Misra. Whitney Tilson close small cap co-investors Chuck Gillman, Jeff Eberwein are at the center. I’ve been told they do nothing but sure things. Former George Soros Investments Portfolio Mgr. Jeff Eberwein Wharton MBA, is ready to take $NOVC http://medmasa.com conceal behind http://healthcare-staffing.com & $730M NOLs. This 8-Member Board connected to past Board Members Jeff Eberwein, Chuck Gillman, Barry Igdaloff, Howard Amster I believe will merge Medmasa/HCS with Hudson Global $HSON (see Jefferey Eberwein Form 4s at $HSON & Form 4s filed at NOVCQ between April-Oct 2015 via his fund Lone Star Value Mgt.). Jeff Eberwein & his clan including Whitney Tilson/Chuck Gillman were introduced to the present day NOVCQ Board Barry Igdaloff, Howard Amster. Wes Edens, Founder of Fortress hide their identity behind Off Balance Sheet OBE Entities Taberna Trups CDOs I and II and former FBR Friedman, Billings, Ramsey now called http://EJFCap.com also hide their identity behind OBE Kodiak CDO I.
Fortress/EJF own at the same time both the only Sr Debt to exit 1st Ch 11 MD and months afterward 31M NOVCQ common (9M NOVCQ common shares plus 22.250M Ten Year Warrants. There are co-conspirators with NOVCQ board of directors that own 40M NOVCQ Common & MassMutual & Jefferies own 40M NOVCQ common shares. Novation Companies Inc. $NOVCQ submerged shareholder plans and value under SEC Rule 15c(2)-11 to sub penny stock that can only be traded today by Expert Investors defined by this SEC Rule. Fortress/EJF Capital paid almost nothing for OBEs yet they have spent at least $2M cash in the last Ch 11 in DE. They have every reason to do something big.
I believe that something will be splitting NOVCQ into two tax free public companies worth BILLIONS plus Hundreds of Millions in annual cash flow in MREIT Dividends & Lucrative Mgt Fees just like Fortress did a LEAF/One Main OMF, Newcastle that is New Residential $NRZ now Rithm Capital $RITM and $GCI formerly New Media NEWM and New Senior $SNR sold for over $2B. $RITM aka $NRZ in 2019 10K documented that shareholders paid Fortress over $250M in Mgt Fees annually, plus dividends. Fortress terminated the NRZ/RITM Mgt Deal for cool $400M (simultaneously changing Name/Symbol to Rithm Capital $RITM). NOVCQ Dark Horse are their plans for NOVCQ only operating unit HCS aka Medmasa http://medmasa.com concealed by CH 11 in DE. Medmasa NOVCQ only operating unit is http://healthcare-staffing.com NOVCQ former MREIT NYSE $NFI now named Novastar Mortgage is the Board, EJF Capital and Fortress ticket to monetizing rights (see Exhibit 2.1 of Q3 2007 10Q Service Rights Transfer Agreement Sec 5.04 that defines these rights as Cleanup Call Rights CCR well know to these MREIT experts) that control billions of rich, seasoned collateral assets ideal to be leveraged and securitized into MREIT dividend & like RITM aka NRZ another external management fee for Fortress and/or EJF. Fortress/EJF Capital then FBR did this with NOVCQ Board Barry Igdaloff, Howard Amster 2000-03 at Dynex Capital NYSE $DX. Ask Igdaloff helpers Thomas Akin former CEO/COB of DX he holds 1.9M of NOVCQ in his fund Talkot Capital. Thomas Bruce Akin sat on DX Board for years with NOVCQ Chairman Igdaloff. Igdaloff served 20 years on DX Board per DX 8K 9/3/2020.This is your chance to do what is right. ====================================== ALTERNATIVES
May 15, 2024 12:04 PM

Fortress, Mubadala complete acquisition of Fortress Investment Group

LYDIA TOMKIWERIN ARVEDLUND

• TWEET
• SHARE
• SHARE
• MORE

REPRINTSPRINT
Drew McKnight and Joshua Pack
Fortress Investment Group, an alternatives manager, and Mubadala Investment Co., the investment arm of Abu Dhabi’s $276 billion sovereign wealth fund, completed their acquisition deal May 15, and as part of the close, Fortress management now owns a 32% equity interest.
Mubadala owns the remaining 68%. The acquisition, through Mubadala Capital, is for the 90.01% of Fortress equity that was held by SoftBank Group Corp., according to a news release. The terms of the deal were not disclosed.

RELATED ARTICLE

Mubadala seeks co-investors for Fortress in effort to clear U.S. security review SoftBank-Fortress deal turns attention to future arrangements with private equity firms
Fortress’s sale of majority equity was approved by the Committee on Foreign Investment in the United States after concessions were made to let Fortress keep data and technology in the U.S., the Financial Times first reported last week.
Fortress, which had $48 billion in assets under management at the end of 2023, said it expects the new joint venture to help it further establish itself in credit and real estate in both public and private markets. Fortress pointed to Mubadala Capital’s global network to help expand client relationships.
“This is a true landmark event for Fortress, for our employees and for the clients we serve,” said Fortress co-CEOs Drew McKnight and Joshua Pack, adding, “We have strengthened alignments of interest, put significant management skin in the game, and deepened our long-term partnership with Mubadala, one of the world’s most highly regarded investors.”
As part of Fortress management now owning a 32% equity interest, its management is entitled to appointment of a majority of board seats. McKnight, Pack and managing partner Jack Neumark were the largest individual investors in the buyout and were joined by about 150 members of the firm.
Mubadala Capital’s CEO and managing director, Hani Barhoush, continues to serve on the Fortress board, a position he has held since 2019 when Mubadala initially invested.
Fortress will continue to operate as an independent investment manager under its own brand and with full autonomy over its investment process and personnel.

1. ALTERNATIVES